TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11753959

Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (ALT) - 4 cycles of intravenous cisplatin (20 mg/m² for 5 days) and 5-fluorouracil (200 mg/m² for 5 days) alternated with three 2-week courses of radiotherapy (20 Gy per course, 2 Gy per day, 5 days per week).
Number of subjects: 136

Group type: COMPARATOR
Intervention: Partly accelerated radiotherapy (PA‐RT) - 75 Gy/40 fractions in 6 weeks.
Number of subjects: 136
Study: 9433591

Group type: EXPERIMENTAL
Intervention: Linkage analysis using MAPMAKER/SIBS and SIBPAL program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis using residuals of Q1 and Q3
Number of subjects: 0
Study: 8335014

Group type: EXPERIMENTAL
Intervention: DTPa vaccine
Number of subjects: 218

Group type: COMPARATOR
Intervention: DTPw vaccine
Number of subjects: 218
Study: 3720707

Group type: EXPERIMENTAL
Intervention: Extended phenytoin sodium capsules (Dilantin Kapseals) - 3 capsules of 100 mg each (276 mg free acid)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Phenytoin oral suspension (Dilantin oral suspension) - 11 ml (275 mg)
Number of subjects: 7
Study: 28735720

Group type: EXPERIMENTAL
Intervention: Aquatic training program (n=17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 32
Study: 27340358

Group type: EXPERIMENTAL
Intervention: Oral E. coli Nissle therapy (2 capsules daily for one month)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (vegetarian diet and topical therapy only)
Number of subjects: 57
Study: 25907781

Group type: EXPERIMENTAL
Intervention: Pre-intervention TEG measurements
Number of subjects: 184
Study: 23554283

Group type: COMPARATOR
Intervention: Creatine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20447097

Group type: EXPERIMENTAL
Intervention: Spherical implantable collamer lens (ICL)
Number of subjects: 126
Study: 18199999

Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (E-EPA)
Number of subjects: 24
Study: 16185307

Group type: EXPERIMENTAL
Intervention: VSL# 3
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12923020

Group type: EXPERIMENTAL
Intervention: Monophasic shock at 200 J
Number of subjects: 227

Group type: COMPARATOR
Intervention: Biphasic shock at 120 J
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Monophasic shock at 360 J
Number of subjects: 227

Group type: COMPARATOR
Intervention: Biphasic shock at 200 J
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Monophasic shocks
Number of subjects: 227

Group type: COMPARATOR
Intervention: Biphasic shocks
Number of subjects: 227
Study: 10784550

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9002328

Group type: EXPERIMENTAL
Intervention: Diet A (cereals, vegetable oil, and animal milk or yoghurt)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Diet B (lactose free, energy from cereals partially replaced by simple sugars)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Treatment algorithm (including locally available foods, vitamin and mineral supplementation, selective use of antibiotics)
Number of subjects: 460
Study: 1463114

Group type: EXPERIMENTAL
Intervention: Identification of EBSLN using a nerve stimulator during dissection by the first author.
Number of subjects: 76

Group type: COMPARATOR
Intervention: No nerve search during dissection executed by a resident.
Number of subjects: 76

Group type: COMPARATOR
Intervention: No nerve search during dissection undertaken by the first author.
Number of subjects: 76
Study: 6475754

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) group
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Usual Care (UC) group
Number of subjects: 12866
Study: 30735266

Group type: EXPERIMENTAL
Intervention: Individualised neonatal parent support programme (four individual nurse-parent dialogues during hospitalisation)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Individualised neonatal parent support programme
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 231
Study: 29510223

Group type: EXPERIMENTAL
Intervention: TSP + ALC
Number of subjects: 225

Group type: COMPARATOR
Intervention: TSP
Number of subjects: 225
Study: 27002354

Group type: EXPERIMENTAL
Intervention: Behavioural intervention targeting adolescent sexual risk behaviours
Number of subjects: 0
Study: 25113081

Group type: EXPERIMENTAL
Intervention: Cortisol and norepinephrine levels in patients with stroke who developed infections on day 3
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Plasma IL-6 and IL-10 levels in patients with stroke who developed infections on day 3
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mortality in patients with infection
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Recovery of immune system post-infection
Number of subjects: 39
Study: 22190134

Group type: EXPERIMENTAL
Intervention: Aerobic exercise during weight regain
Number of subjects: 40

Group type: COMPARATOR
Intervention: No exercise during weight regain
Number of subjects: 40
Study: 20717077

Group type: EXPERIMENTAL
Intervention: MLC2.5
Number of subjects: 43

Group type: COMPARATOR
Intervention: MLC5
Number of subjects: 43
Study: 17667684

Group type: EXPERIMENTAL
Intervention: Tissue engineering technique with bone marrow stem cells in a resorbable matrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional iliac crest bone graft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimally invasive iliac crest bone graft
Number of subjects: 0
Study: 15842914

Group type: EXPERIMENTAL
Intervention: Non-instrumented group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Instrumented group
Number of subjects: 81
Study: 12173728

Group type: EXPERIMENTAL
Intervention: Acarbose plus glibenclamide
Number of subjects: 84

Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 84

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 9449728

Group type: EXPERIMENTAL
Intervention: Limited-ventilation group (peak inspiratory pressure maintained at 30 cm of water or less, tidal volume at 8 ml per kilogram or less)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (peak inspiratory pressure allowed to rise as high as 50 cm of water, tidal volume at 10 to 15 ml per kilogram)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Limited-ventilation group
Number of subjects: 120
Study: 7657765

Group type: EXPERIMENTAL
Intervention: Normal HOS scores (mean HOS score 70.0%)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Subnormal HOS scores (mean HOS score 36.7%)
Number of subjects: 27
Study: 2627387

Group type: EXPERIMENTAL
Intervention: IV labetalol at doses of 0.25, 0.5, 0.75, or 1 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV saline (placebo)
Number of subjects: 60
Study: 4706912

Group type: EXPERIMENTAL
Intervention: Selective vagotomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Selective vagotomy plus pyloroplasty
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy plus pyloroplasty
Number of subjects: 40
Study: 31901229

Group type: EXPERIMENTAL
Intervention: Peri-articular injection (PAI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-articular injection (IAI)
Number of subjects: 60
Study: 31254462

Group type: EXPERIMENTAL
Intervention: Prolonged capecitabine chemotherapy (1000 mg/m² per day for 2 weeks, repeated every 3 weeks for 8 cycles at most)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Prolonged capecitabine chemotherapy
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (no prolonged chemotherapy)
Number of subjects: 212
Study: 28323965

Group type: EXPERIMENTAL
Intervention: C-terminal peptide-modified hGH (MOD-4023) at doses of 0.25, 0.48, or 0.66 mg/kg/wk
Number of subjects: 53

Group type: COMPARATOR
Intervention: Daily recombinant human GH (r-hGH) at a dose of 0.24 mg/kg/wk
Number of subjects: 53
Study: 25293405

Group type: EXPERIMENTAL
Intervention: High levels of psychological distress
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Labile moods
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Less ability to regulate emotional states
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 19
Study: 23142669

Group type: EXPERIMENTAL
Intervention: LIBER8 intervention (Linking Individuals Being Emotionally Real)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2BFit (weight management control condition)
Number of subjects: 0
Study: 21044831

Group type: EXPERIMENTAL
Intervention: SOD/gliadin supplement (500 mg/day for 12 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19785256

Group type: EXPERIMENTAL
Intervention: Dynamic group (received cues, strategy training, and feedback during an object search task)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard pretests and posttests of unilateral neglect)
Number of subjects: 40
Study: 16788927

Group type: EXPERIMENTAL
Intervention: Porfimer sodium photodynamic therapy (ps‐PDT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant thermal ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor therapy
Number of subjects: 0
Study: 15294219

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12011968

Group type: EXPERIMENTAL
Intervention: HR (Paroven, Venoruton; 0‐(beta‐hydroxyethyl)‐rutosides)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 9715584

Group type: EXPERIMENTAL
Intervention: High-EE relatives
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patients from high-EE families
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patients from low-EE families
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-EE families
Number of subjects: 48
Study: 7641249

Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 2666451

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 13342

Group type: EXPERIMENTAL
Intervention: Group systematic desensitization (n = 8)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Group flooding (n = 7)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Group discussion‐placebo control treatment (n = 4)
Number of subjects: 19
Study: 31899509

Group type: EXPERIMENTAL
Intervention: Active transcranial random noise stimulation (30 minutes, 2 mA direct current offset, random noise range of 2 mA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham transcranial random noise stimulation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Active transcranial random noise stimulation
Number of subjects: 66
Study: 28233459

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily plus vitamin D 60,000 units once weekly
Number of subjects: 28

Group type: COMPARATOR
Intervention: Simvastatin 40 mg daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vitamin D 60,000 units once weekly
Number of subjects: 28
Study: 25500317

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (155-195 U)
Number of subjects: 688
Study: 23471421

Group type: EXPERIMENTAL
Intervention: Centralized depression care (patient preference for problem-solving treatment via telephone or Internet, pharmacotherapy, both, or neither) for 6 months (active treatment group; n = 73)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (locally determined depression care after physician notification about the patient's depressive symptoms; usual care group; n = 77)
Number of subjects: 150
Study: 21214584

Group type: EXPERIMENTAL
Intervention: Buffy coat (BC) PLTs
Number of subjects: 14

Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP) PLTs
Number of subjects: 14
Study: 19272066

Group type: EXPERIMENTAL
Intervention: Lower septal pacing
Number of subjects: 36

Group type: COMPARATOR
Intervention: RV apical pacing
Number of subjects: 36
Study: 17912670

Group type: EXPERIMENTAL
Intervention: Cerasorb with PRP
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cancellous bone from the iliac crest
Number of subjects: 26
Study: 15566540

Group type: EXPERIMENTAL
Intervention: Training as a complex intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative and qualitative approaches
Number of subjects: 0
Study: 11507918

Group type: EXPERIMENTAL
Intervention: Oral hygiene program (instruction on brushing, flossing, and professional tooth cleaning)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Negative control (10 students with no oral hygiene training)
Number of subjects: 55
Study: 9022536

Group type: EXPERIMENTAL
Intervention: 100 mg D‐alpha‐tocopheryl acetate plus 250 mg slow‐release ascorbic acid twice a day (n = 20)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 100 mg D‐alpha‐tocopheryl acetate twice a day (n = 20)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 250 mg ascorbic acid twice a day (n = 21)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 250 mg slow‐release ascorbic acid twice a day (n = 21)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 30 mg coenzyme Q10 in oil three times a day (n = 20)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 30 mg coenzyme Q10 as granulate three times a day (n = 20)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo twice a day (n = 20)
Number of subjects: 142
Study: 7932284

Group type: EXPERIMENTAL
Intervention: 4 x 50 micrograms GHRH
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31828820

Group type: EXPERIMENTAL
Intervention: KTP laser ablation
Number of subjects: 24

Group type: COMPARATOR
Intervention: CO2 laser cordectomy
Number of subjects: 24
Study: 31158801

Group type: EXPERIMENTAL
Intervention: Inhibitory control training (5-week computerized and adaptive training)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active control training
Number of subjects: 60
Study: 28957341

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy course
Number of subjects: 101

Group type: COMPARATOR
Intervention: 14-day quadruple regimen
Number of subjects: 101
Study: 25689986

Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 25
Study: 23907442

Group type: EXPERIMENTAL
Intervention: Fotonovela (Entertainment-Education)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study: 21827533

Group type: EXPERIMENTAL
Intervention: Videogame training for 2.5 hours across 5 days
Number of subjects: 0
Study: 16096787

Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7 (A(1-7)) administered at a dose of 100 microg/kg per day for at least 10 days after chemotherapy.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Filgrastim (control group) administered over three cycles of chemotherapy.
Number of subjects: 20
Study: 12885265

Group type: EXPERIMENTAL
Intervention: Tazarotene cream 0.1% applied to face (standard application)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tazarotene cream 0.1% applied to 15% body surface area (exaggerated application)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tazarotene cream 0.1% applied to face (standard application) in photodamaged skin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tazarotene cream 0.1% applied to 15% body surface area (exaggerated application) in photodamaged skin
Number of subjects: 52
Study: 11115436

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (125 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Terbutaline (5 x 500 microg inhaled)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (first day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline solution (first day)
Number of subjects: 25
Study: 9213864

Group type: EXPERIMENTAL
Intervention: Somatostatin (SS) perfusion at 250 mcg/h for 48 hours
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (P) - physiologic saline 0.9%
Number of subjects: 47
Study: 8232171

Group type: EXPERIMENTAL
Intervention: HIV counseling interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 0
Study: 4024910

Group type: EXPERIMENTAL
Intervention: TTS‐scopolamine (5 micrograms/h, one and two patches)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TTS‐scopolamine (two patches)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (100 mg)
Number of subjects: 16
Study: 31330901

Group type: EXPERIMENTAL
Intervention: Longer duration of breastfeeding
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Dietary intake of fish, fruits, and vegetables
Number of subjects: 212
Study: 29562883

Group type: COMPARATOR
Intervention: Multi-component, community-sport based program targeting prevention, promotion and early intervention for mental health.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Messaging campaign aimed at adolescents to enhance mental health literacy.
Number of subjects: 0
Study: 27581812

Group type: EXPERIMENTAL
Intervention: Neck suction at -60 Torr during moderate-intensity exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neck suction at -60 Torr during low-intensity exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15
Study: 24810956

Group type: EXPERIMENTAL
Intervention: tRNS (transcranial random noise stimulation) applied to unilateral M1 (primary motor cortex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral tDCS (transcranial direct current stimulation) applied to unilateral M1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral tDCS applied to M1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimulation of the right temporal lobe
Number of subjects: 0
Study: 23278574

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20016142

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Paricalcitol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall Ca absorption
Number of subjects: 22

Group type: COMPARATOR
Intervention: Serum PTH, Ca, phosphorus (P), or Ca x P
Number of subjects: 22
Study: 17296655

Group type: EXPERIMENTAL
Intervention: Three-times-daily (TID) heparin dosing
Number of subjects: 7978

Group type: COMPARATOR
Intervention: Twice-daily (BID) heparin dosing
Number of subjects: 7978
Study: 15613405

Group type: EXPERIMENTAL
Intervention: Single dose testosterone administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 18
Study: 12186604

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50-micro g tablet once daily)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and fludrocortisone
Number of subjects: 300
Study: 10452638

Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg/d)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 7889438

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 2357869

Group type: EXPERIMENTAL
Intervention: Bromfenac 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromfenac 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromfenac 10 mg and 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromfenac 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 695520

Group type: EXPERIMENTAL
Intervention: Rimantadine (300 mg on day 1, 200 mg on day 2, 100 mg on days 3 and 4; contacts received 100 mg for 7 to 10 days)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Rimantadine (prophylactic use)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Symptomatic drugs (control group)
Number of subjects: 146
Study: 30630815

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg and 75 mg on two following days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg BID for 5 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study: 29388926

Group type: EXPERIMENTAL
Intervention: Personalized therapy including robotized mechanotherapy, stabilography, neuro-muscular stimulation, kinesiotherapy, physical therapy, ergotherapy, massage, etc.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 68
Study: 26597741

Group type: EXPERIMENTAL
Intervention: Aspirin 60 mg/d
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 23581554

Group type: EXPERIMENTAL
Intervention: Perinatal risk factors (maternal gestational smoking and drug use, early labor, low birth weight, infant breathing problems)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Control for family socioeconomic status (SES) and maternal symptoms of ADHD and depression
Number of subjects: 719

Group type: COMPARATOR
Intervention: Control for the number of child comorbidities plus SES and maternal symptoms
Number of subjects: 719
Study: 21425567

Group type: EXPERIMENTAL
Intervention: Modified Huopo Xialing Decoction (HXD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Domperidone (Control)
Number of subjects: 50
Study: 19767074

Group type: EXPERIMENTAL
Intervention: Oral prednisone (30mg/d for 14 days)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Optimized inhaled fluticasone dose
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Loss of control
Number of subjects: 73

Group type: COMPARATOR
Intervention: Predicted values from Olin et al
Number of subjects: 73

Group type: COMPARATOR
Intervention: Predicted values from Travers et al
Number of subjects: 73

Group type: COMPARATOR
Intervention: Predicted values from Dressel et al
Number of subjects: 73
Study: 17363859

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy group (8 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 20